...
首页> 外文期刊>Drug delivery. >A novel matrix dispersion based on phospholipid complex for improving oral bioavailability of baicalein: preparation, in vitro and in vivo evaluations
【24h】

A novel matrix dispersion based on phospholipid complex for improving oral bioavailability of baicalein: preparation, in vitro and in vivo evaluations

机译:基于磷脂复合物的新型基质分散体,可改善黄ical素的口服生物利用度:制备,体内和体外评估

获取原文

摘要

Abstract Phospholipid complex is one of the most successful approaches for enhancing oral bioavailability of poorly absorbed plant constituents. But the sticky property of phospholipids results in an unsatisfactory dissolution of drugs. In this study, a matrix dispersion of baicalein based on phospholipid complex (BaPC-MD) was first prepared by a discontinuous solvent evaporation method, in which polyvinylpyrrolidone-K30 (PVP-K30) was employed for improving the dispersibility of baicalein phospholipid complex (BaPC) and increasing dissolution of baicalein. The combination ratio of baicalein and phospholipids in BaPC-MD was 99.39% and baicalein was still in a complete complex state with phospholipid in BaPC-MD. Differential scanning calorimetry (DSC), X-ray diffraction (XRD), scanning electron microscopy (SEM) and Fourier Transform Infrared (FTIR) analyzes demonstrated that baicalein was fully transformed to an amorphous state in BaPC-MD and phospholipid complex formed. The water-solubility and n-octanol solubility of baicalein in BaPC-MD significantly increased compared with those of pure baicalein. Compared with baicalein and BaPC, the cumulative dissolution of BaPC-MD at 120?min increased 2.77- and 1.23-fold, respectively. In vitro permeability study in Caco-2 cells indicated that the permeability of BaPC-MD was remarkably higher than those of baicalein and BaPC. Pharmacokinetic study showed that the average Cmax of BaPC-MD was significantly increased compared to baicalein and BaPC. AUC0–14?h of BaPC-MD was 5.01- and 1.91-fold of baicalein and BaPC, respectively. The novel BaPC-MD significantly enhanced the oral bioavailability of baicalein by improving the dissolution and permeability of baicalein without destroying the complexation state of baicalein and phospholipids. The current drug delivery system provided an optimal strategy to significantly enhance oral bioavailability for poorly water-soluble drugs.
机译:摘要磷脂复合物是提高吸收不良的植物成分口服生物利用度的最成功方法之一。但是磷脂的粘性导致药物的溶解不令人满意。在这项研究中,首先通过不连续溶剂蒸发法制备了基于磷脂复合物(BaPC-MD)的黄ical素基质分散体,其中聚乙烯基吡咯烷酮-K30(PVP-K30)用于改善黄improving素磷脂复合物(BaPC)的分散性)并增加黄ical素的溶出度。 BaPC-MD中黄ical素和磷脂的结合率为99.39%,BaPC-MD中黄ical素与磷脂仍处于完全复合状态。差示扫描量热法(DSC),X射线衍射(XRD),扫描电子显微镜(SEM)和傅立叶变换红外(FTIR)分析表明,黄ical素在BaPC-MD中完全转化为非晶态,并形成了磷脂复合物。黄pure素在BaPC-MD中的水溶性和正辛醇溶解度比纯黄ical素显着增加。与黄ical素和BaPC相比,BaPC-MD在120?min的累积溶出分别增加了2.77倍和1.23倍。在Caco-2细胞中进行的体外通透性研究表明,BaPC-MD的通透性显着高于黄ical素和BaPC。药代动力学研究表明,与黄ical素和BaPC相比,BaPC-MD的平均C max 显着增加。 BaPC-MD的AUC 0-14?h 分别为黄ical素和BaPC的5.01倍和1.91倍。新型BaPC-MD通过改善黄ical素的溶解性和渗透性而不会破坏黄ical素和磷脂的络合状态,从而显着提高了黄ical素的口服生物利用度。当前的药物输送系统提供了一种最佳策略,可显着提高水溶性差的药物的口服生物利用度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号